Pharmacology and Therapeutics Advisory Committee (PTAC)
PTAC is PHARMAC’s primary clinical advisory committee. PTAC's role is to provide objective clinical advice to the Board of PHARMAC.
PTAC considers and makes recommendations on, amongst other things:
- applications for funding pharmaceuticals
- amendments to the Pharmaceutical Schedule, where there are clinical issues to consider
- the management of the Pharmaceutical Schedule
- the need for reviews of specific drugs, or groups of drugs.
PTAC is made up of senior health practitioners from a range of specialities, who consider clinical evidence around funding applications, and take into account PHARMAC's Factors for Consideration before making recommendations to PHARMAC.
PTAC subcommittees provide more specialised advice, on therapeutic areas such as cancer, diabetes or heart disease.
PTAC meets 4 times a year to review funding applications from pharmaceutical suppliers, health professionals and consumer groups.
The table shows:
- the dates of PTAC meetings to the end of 2017
- the last possible dates for PHARMAC to receive funding applications so they can be considered for inclusion in the PTAC agenda.
|PTAC meeting date:||Applications (3 copies) to PHARMAC before:||Additional copies of applications (3 copies) to PHARMAC before:|
|3 & 4 November 2016||22 August 2016||16 September 2016|
|9 & 10 February 2017||7 November 2016||16 December 2016|
|4 & 5 May 2017||13 February 2017||17 March 2017|
|10 & 11 August 2017||22 May 2017||16 June 2017|
|9 & 10 November 2017||21 August 2017||15 September 2017|
Note that funding applications are made to PHARMAC, not PTAC.
When submitting a funding application, please address it to:
40 Mercer Street
For making an application, please use the Guidelines for funding applications to PHARMAC [PDF, 445 KB].
The guidelines for funding applications require the following when submitting an application:
- In order for PHARMAC to assess the proposal and ensure that the application is complete, please provide the following with the initial copy of the funding application:
- 3 spiral bound copies of the application (including synopsis and all supporting references), and
- an electronic copy of the application (including synopsis and all supporting references).
- Once the initial copy of the funding application has been assessed, PHARMAC may submit it to PTAC for further consideration.
If it is submitted to PTAC, PHARMAC will notify the applicant, and the applicant must provide:
- 3 additional spiral bound copies of the application (including synopsis and all supporting references), and
- a sample of the pharmaceutical (if the application is for funding of a new pharmaceutical or new brand of pharmaceutical).
If PHARMAC decides not to submit the application to PTAC, it will inform the applicant of the reasons for this.
If you have any additional questions regarding submitting applications to PTAC, contact the PTAC Secretary at email@example.com or +64 (0)4 916 7512.
Contact PTAC by emailing the PTAC Secretary.
PTAC members are appointed by the Director-General of Health, in consultation with the PHARMAC Board. This process is guided by an appointment protocol [PDF, 72 KB].
Members of PTAC either apply directly or are nominated by professional medical bodies, such as the Royal New Zealand College of General Practitioners and the Royal Australasian College of Physicians.
PTAC's members are:
- Mark Weatherall (Chair)
BA, MBChB, MApplStats, FRACP
- Melissa Copland
PhD, BPharm(Hons), RegPharmNZ, FNZCP
- Stuart Dalziel
MBChB, PhD, FRACP
- Alan Fraser
MB, ChB, MD, FRACP
- Sean Hanna
MB ChB, FRNZCGP, FRACGP, PGDipGP, PGCertClinEd
- Jennifer Martin
MBChB, MA(Oxon.), FRACP, PhD
- Graham Mills
MBChB, MTropHlth, MD, FRACP
- Giles Newton-Howes
BA, BSc, MBChB, MRCPsych, PostDip BD, FRANZCP
- Marius Rademaker
BM (Soton), MRCP (UK), JCHMT Accreditation, DM, FRCP (Edin), FRACP
- Jane Thomas
MB ChB, FANZCA, FFPMANZCA
- Simon Wynn Thomas
BMedSci (UK), MRCP (UK), MRCGP (UK), DFFP, FRNZCGP
Last updated: 16 September 2016